Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Assets (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Assets for 11 consecutive years, with $842.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets fell 29.29% to $842.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $842.1 million, a 29.29% decrease, with the full-year FY2025 number at $842.1 million, down 29.29% from a year prior.
  • Assets was $842.1 million for Q4 2025 at Intellia Therapeutics, down from $925.3 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.5 billion in Q4 2022 to a low of $672.2 million in Q2 2021.
  • A 5-year average of $1.1 billion and a median of $1.2 billion in 2024 define the central range for Assets.
  • Peak YoY movement for Assets: skyrocketed 191.12% in 2021, then decreased 29.29% in 2025.
  • Intellia Therapeutics' Assets stood at $1.3 billion in 2021, then rose by 17.43% to $1.5 billion in 2022, then dropped by 14.42% to $1.3 billion in 2023, then decreased by 8.45% to $1.2 billion in 2024, then fell by 29.29% to $842.1 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Assets are $842.1 million (Q4 2025), $925.3 million (Q3 2025), and $898.9 million (Q2 2025).